428 related articles for article (PubMed ID: 27097892)
1. The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK.
Rosario DJ; Davey P; Green J; Greene D; Turner B; Payne H; Kirby M
World J Urol; 2016 Dec; 34(12):1601-1609. PubMed ID: 27097892
[TBL] [Abstract][Full Text] [Related]
2. [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].
Tschöpe C; Kherad B; Spillmann F; Schneider CA; Pieske B; Krackhardt F
Herz; 2016 Dec; 41(8):697-705. PubMed ID: 27083586
[TBL] [Abstract][Full Text] [Related]
3. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
4. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
Higano CS
Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
[TBL] [Abstract][Full Text] [Related]
5. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.
Shore ND; Abrahamsson PA; Anderson J; Crawford ED; Lange P
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):7-15. PubMed ID: 22751146
[TBL] [Abstract][Full Text] [Related]
6. [Cardiovascular risk patients under androgen deprivation therapy: Lower risk with GnRH antagonists compared to LHRH agonists?].
Merseburger AS; Sedding D; Hüter K
Urologe A; 2016 Feb; 55(2):218-25. PubMed ID: 26637324
[TBL] [Abstract][Full Text] [Related]
7. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.
Greiman AK; Keane TE
Curr Urol Rep; 2017 Jun; 18(6):41. PubMed ID: 28417429
[TBL] [Abstract][Full Text] [Related]
8. Gonadotropin-releasing hormone antagonist: A real advantage?
Kimura T; Sasaki H; Akazawa K; Egawa S
Urol Oncol; 2015 Jul; 33(7):322-8. PubMed ID: 26070474
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist.
Albertsen PC; Klotz L; Tombal B; Grady J; Olesen TK; Nilsson J
Eur Urol; 2014 Mar; 65(3):565-73. PubMed ID: 24210090
[TBL] [Abstract][Full Text] [Related]
10. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials.
Abufaraj M; Iwata T; Kimura S; Haddad A; Al-Ani H; Abusubaih L; Moschini M; Briganti A; Karakiewicz PI; Shariat SF
Eur Urol; 2021 Jan; 79(1):44-53. PubMed ID: 32605859
[TBL] [Abstract][Full Text] [Related]
11. GnRH antagonists in the treatment of advanced prostate cancer.
Pommerville PJ; de Boer JG
Can J Urol; 2010 Apr; 17(2):5063-70. PubMed ID: 20398443
[TBL] [Abstract][Full Text] [Related]
12. Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist.
Margel D; Ber Y; Peer A; Shavit-Grievink L; Pinthus JH; Witberg G; Baniel J; Kedar D; Rosenbaum E
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):177-185. PubMed ID: 32737420
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice.
Davey P; Kirby MG
World J Urol; 2021 Feb; 39(2):307-315. PubMed ID: 32979057
[TBL] [Abstract][Full Text] [Related]
14. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
Steinberg M
Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
[TBL] [Abstract][Full Text] [Related]
15. [Cost effectiveness of GnRH antagonists in patients with prostate cancer and cardiovascular risk : Comparative analysis against Leuprorelin by the Number Needed to Treat].
Anderson D; Lehmann J; Ecker T; Vosgerau S; Donatz V
Urologe A; 2017 Jul; 56(7):917-924. PubMed ID: 28405705
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.
Scailteux LM; Vincendeau S; Balusson F; Leclercq C; Happe A; Le Nautout B; Polard E; Nowak E; Oger E
Eur J Cancer; 2017 May; 77():99-108. PubMed ID: 28390298
[TBL] [Abstract][Full Text] [Related]
17. Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.
George DJ; Dearnaley DP
Future Oncol; 2021 Nov; 17(33):4431-4446. PubMed ID: 34409852
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation therapy and side effects: are GnRH antagonists safer?
Freedland SJ; Abrahamsson PA
Asian J Androl; 2021; 23(1):3-10. PubMed ID: 32655041
[TBL] [Abstract][Full Text] [Related]
19. Degarelix: a new approach for the treatment of prostate cancer.
Persson BE; Kold Olesen T; Jensen JK
Neuroendocrinology; 2009; 90(3):235-44. PubMed ID: 19602868
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]